trending Market Intelligence /marketintelligence/en/news-insights/trending/pyhl6862skmsbsovpq2bxa2 content esgSubNav
In This List

Gilead Sciences licenses California-based company's drug discovery technology

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


Gilead Sciences licenses California-based company's drug discovery technology

Gilead Sciences Inc. said it entered a license agreement with San Francisco-based Trianni Inc. to use its drug discovery platform.

The financial details of the agreement were not disclosed in a Sept. 4 news release.

Trianni's transgenic human monoclonal antibody discovery platform uses genetically engineered mice to generate antibodies that can be effective in humans.